Loading
A phase 2 trial of Lorlatinib in non-small-cell lung cancer and small-cell lung cancer, run by CStone Pharmaceuticals, active and no longer recruiting.
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05297890 by CStone Pharmaceuticals, with 70 participants enrolled, started 2022-05-27 and due to reach its primary completion in 2023-12-26. Interventions recorded: Lorlatinib. Conditions listed: Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares CStone Pharmaceuticals, Small-molecule kinase inhibitors.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/